Washington, April 28: The U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) has taken significant action against a synthetic opioid network linked to Mexico’s notorious Sinaloa cartel, imposing sanctions on 23 individuals and entities. According to the U.S. Embassy in India, Indian law enforcement agencies played a vital role in combating this criminal network involved in drug trafficking.
U.S. officials stated that this network supplied precursor chemicals used in the production of deadly drugs like fentanyl, which were then transformed into synthetic narcotics in illegal laboratories located in Mexico.
Following this action, the U.S. Embassy in New Delhi praised India’s assistance, noting that the involvement of Indian law enforcement agencies has been “critical” in disrupting this criminal network.
In a statement, the embassy said, “The United States deeply appreciates its partnership with Indian law enforcement, which has significantly contributed to dismantling key components of this criminal network. These cartels provided precursor chemicals used for the production and trafficking of illegal drugs.”
According to the U.S. Treasury, these networks often mislabel chemicals as “safe substances” to exploit international supply chains. These chemicals were then sent to drug labs in Mexico and Guatemala, from where the finished drugs reached markets in the United States.
Treasury Secretary Scott Basent was quoted in the statement, emphasizing, “President Trump has made it clear that terrorist organizations will not be allowed to wreak havoc in our borders and communities. The Treasury will continue to target every phase of the opioid supply chain to keep America safe and prevent deaths caused by fentanyl.”
Officials have noted that synthetic drugs like fentanyl and methamphetamine are responsible for thousands of deaths in the U.S. each year, making their regulation a critical national security issue.
This action is part of the U.S. government’s “whole-of-government” strategy, which targets every level of the drug supply chain—chemical suppliers, brokers, financial networks, and trafficking channels.
Leave a Comment